Publication Name	World Journal of Clinical Cases
Manuscript ID	40130
Country	Taiwan

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
Manuscript Source	Unsolicited Manuscript
All Author List	Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen and Deng-Chyang Wu
Funding Agency and Grant Number
Corresponding Author	Kuan-Yang Chen, MA, Attending Doctor, Department of Gastroenterology, Taipei City Hospital, 11F., No.10, Sec. 4, Renai Rd., Da-an Dist, Taipei 10629, Taiwan. daa13@tpech.gov.tw
Key Words	Helicobacter pylori; Cytochrome P450 2C19; Interleukin-1β; Hybrid therapy; Rabeprazole
Core Tip	In this study, we investigated the efficacy of hybrid therapy as a first-line treatment for Helicobac­ter pylori eradication and evaluated the independent predictor associated with eradication efficacy, including cytochrome P450 2C19, interleukin-1β (IL-1β)-511 poly­morphism and antibiotic resistance. This study is pilot work investigating the impact of the IL-1β-511 polym­orphism on the eradication rate of hybrid therapy.
Citation	Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520

Received	2018-06-09 08:28
Peer-Review Started	2018-06-10 13:55
To Make the First Decision	2018-07-10 09:28
Return for Revision	2018-07-12 06:52
Revised	2018-08-08 06:38
Second Decision	2018-08-30 08:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-08-30 17:28
Articles in Press	2018-08-30 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor	2018-09-10 17:24
Typeset the Manuscript	2018-10-22 01:22

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com